{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:39:18Z","timestamp":1789007958680,"version":"build-2803163510"},"reference-count":14,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2014]]},"abstract":"<jats:p>Recommendations related to ocular, mucosal and cutaneous involvement of Beh\u00e7et's disease (BD) are mainly evidence-based, but in cases of vascular, neurological and gastrointestinal involvement there are no guidelines to define the best treatment strategy. We report three adult patients with BD, who received an interleukin-1\u03b2 inhibitor by subcutaneous injections, canakinumab (at the dosage of 150 mg every 6 weeks), after failure shown by corticosteroids and different combinations of immunosuppressant agents. The prompt and sustained clinical efficacy demonstrated by canakinumab as a monotherapy supports the opportunity of using this specific anti-interleukin-1\u03b2 agent as a valid therapeutic option for resistant or refractory BD. Open trials and observational studies should be performed to test canakinumab efficacy on a larger number of patients. The most appropriate dosage and intervals between administrations should be decided according to the individual patient, severity or recurrence of clinical manifestations and major organ involvement.<\/jats:p>","DOI":"10.1159\/000358125","type":"journal-article","created":{"date-parts":[[2014,3,12]],"date-time":"2014-03-12T07:51:55Z","timestamp":1394610715000},"page":"211-214","source":"Crossref","is-referenced-by-count":77,"title":["Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory Beh\u00e7et's Disease: A Case Series"],"prefix":"10.1159","volume":"228","author":[{"given":"Antonio","family":"Vitale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Rigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Caso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppina","family":"Brizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orso Maria","family":"Lucherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2014,3,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92643-V"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200301000-00006"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1566-4"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/art.23345"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-006-0425-y"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.09.002"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2013.779727"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201383"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-4-200808190-00016"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-155143"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.3"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.10.008"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/485103"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-003-0400-6"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/358125","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/358125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:34:29Z","timestamp":1745433269000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000358125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,6,1]]},"published-print":{"date-parts":[[2014,6,10]]}},"URL":"https:\/\/doi.org\/10.1159\/000358125","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}